Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 256 clinical trials
None
Comparative Efficacy and Safety of Sugammadex and Neostigmine

general anesthesia, NMBA is needed to relax the muscles of the whole body. Its purpose is to assist the placement of the endotracheal tube, avoid the participant's injury due to involuntary movements, and

  • 40 views
  • 10 Sep, 2021
  • 1 location
None
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is

apomorphine
dyskinesia
levodopa
  • 0 views
  • 22 Oct, 2021
  • 33 locations
None
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA/DDCI in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Carbidopa and benserazide are both …

  • 0 views
  • 04 Aug, 2021
  • 1 location
None
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.

tumor necrosis factor
microbiota
enemas
fecal microbiota transplantation
vedolizumab
  • 0 views
  • 16 Sep, 2021
  • 1 location
None
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study. The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP. …

  • 1 views
  • 15 Nov, 2021
  • 31 locations
None
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

hyperkinetic movement disorders, namely chorea in Huntington's disease (HD) and tardive dyskinesia (TD). Currently, there is no approved treatment available for Dyskinesia in cerebral palsy (DCP). The

  • 181 views
  • 14 Nov, 2021
  • 81 locations
None
Transcranial Ultrasound Therapy of Essential Tremor

Context. Essential tremor (ET) is a common disease, disabling in severe forms and resistant to drug treatment. In patients with severe ET, invasive neurosurgical technique such as deep brain stimulation of the Ventral Intermediate (VIM) nucleus of the thalamus is used. Focused ultrasound therapy, creating a small lesion of VIM …

movement disorder
MRI
depression
brain stimulation
  • 74 views
  • 24 Jan, 2021
  • 1 location
None
Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache

: Headaches are a common complaint presenting to the emergency department (ED), accounting for 1-2% of all ED visits, with migraines as the second most common primary headache syndrome. Patients that ultimately present to the ED have failed outpatient therapy and exhibit severe and persistent symptoms. Treatment options have been …

pain relief
acute treatment
metoclopramide
dihydroergotamine
nausea
  • 286 views
  • 07 Nov, 2020
  • 1 location
None
Amantadine for COVID-19

Introduction Corona virus disease 19 (COVID-19) is a devastating pandemic. By early February 2021, more than 102 million people were infected globally with more than 2.2 million reported deaths. Current treatments are approved for hospitalized patients with severe COVID-19 only. No treatment is approved to prevent progression to severe COVID-19 …

  • 0 views
  • 17 Oct, 2021
  • 1 location
None
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist. This

dopamine
antipsychotics
movement disorder
human chorionic gonadotropin
schizophrenia
  • 210 views
  • 22 Aug, 2021
  • 1 location